By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Esperion Therapeutics, Inc. 

3621 S. State Street
695 KMS Place
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-0506 Fax: 734-332-0516


SEARCH JOBS
Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.

The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.

Key Management:

  • Roger Newton, Ph.D.
    President and CEO
  • Timothy Mayleben
    Chief Operating Officer and CFO

    Last Updated: 01-18-05

    Key Statistics


    Email: info@esperion.com
    Ownership: Public

    Web Site: Esperion Therapeutics, Inc.
    Employees:
    Symbol: ESPR
     



  • Industry
    Biotechnology






    Company News
    Esperion Therapeutics, Inc. (ESPR) Prices Public Offering Of Common Stock 10/16/2014 9:30:28 AM
    Esperion Therapeutics, Inc. (ESPR) Announces Proposed Public Offering Of Common Stock 10/15/2014 1:55:38 PM
    Esperion Therapeutics, Inc. (ESPR)'s ETC-1002-008 Succeeds In Lowering LDL Cholesterol 10/2/2014 5:55:49 AM
    Esperion Therapeutics, Inc. (ESPR)To Present At BioCentury’s Newsmakers In The Biotech Industry Conference 9/23/2014 9:44:15 AM
    Esperion Therapeutics, Inc. (ESPR) Provides Etc-1002 Development Program Update; Reports Second Quarter 2014 Financial Results 8/12/2014 8:25:22 AM
    Esperion Therapeutics, Inc. (ESPR) To Provide Second Quarter 2014 Results 8/6/2014 8:42:48 AM
    Esperion Therapeutics, Inc. (ESPR) Announces Initiation Of A Phase 2 Clinical Study Of ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/24/2014 10:58:28 AM
    Esperion Therapeutics, Inc. (ESPR) To Host Inaugural Analyst And Investor Day 7/17/2014 11:27:03 AM
    Esperion Therapeutics, Inc. (ESPR) To Host Inaugural Analyst And Investor Day 7/17/2014 11:08:49 AM
    Esperion Therapeutics, Inc. (ESPR) Announces The Appointment Of Gilbert S. Omenn, M.D., Ph.D. To Board Of Directors 6/26/2014 7:33:55 AM
    12345678
    //-->